ClinicalTrials.gg
CompletedNCT05446142ERBAUpdated Feb 23, 2024Results posted

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

A Phase 1 interventional study of Encorafenib capsule formulation (CAP) and Encorafenib first formulation in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Relative bioavailability study to evaluate the pharmacokinetics of two new encorafenib formulations

Read the detailed description

In order to decrease the size of the current formulated encorafenib capsule and improve the physical stability, 2 new encorafenib tablet formulations have been developed.

This study is intended to select the optimal tablet formulation for commercialization based on the tablet pharmacokinetics.

A preliminary assessment of the effect of a proton-pump inhibitor on the pharmacokinetics of the 2 encorafenib tablet formulations will also be conducted to assist in the formulation selection.

02

Conditions studied

  • Healthy

Keywords

  • Encorafenib
  • Rabeprazole
  • Healthy adult participants
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be male or female of non- of 18 years of age or older, inclusive, at the time of signing the document.
  • Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • of 17.5 to 30.5 kg/meters squared; and a body weight >50 kg (110 lb).
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document and the protocol.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease. Evidence of any active and uncontrolled bacterial or viral infection.
  • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  • History of infection, , or ; positive testing for human immunodeficiency virus, Hepatitis B surface antigen, Hepatitis B core antibody or hepatitis C virus antibody. Hepatitis B vaccination is allowed.
  • Positive COVID-19 test at first admission.
  • Other medical or psychiatric conditions, laboratory test abnormalities, other conditions or situations related to COVID-19 pandemic or, in the investigator's judgment, make the participant inappropriate for the study.
  • Use of prescription or non-prescription medications within 7 days prior to the first dose of encorafenib with the exception of moderate/potent inducers which are prohibited within 14 days plus 5 half-lives prior to the first dose.
  • History of known sensitivity to rabeprazole, substituted benzimidazoles or to any component of the rabeprazole formulation.
  • Previous administration with an product (drug or vaccine) within 30 days.
  • Known to encorafenib or its .
  • A positive urine drug or cotinine test.
  • Screening supine blood pressure ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
  • Baseline standard 12 lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  • or alanine aminotransferase level ≥ 1.5 × .
  • Total level ≥1.5 × upper limit of normal.
  • Estimated \<60 ml/min/1.73 m2
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Four Period Treatment Sequence: PPI Effect

    Participants will receive a single encorafenib dose formulation, a single encorafenib dose of the formulated capsule (CAP), and a single encorafenib dose of the formulation after administration of 20 mg rabeprazole every evening for 5 days.

    Drug: Encorafenib capsule formulation (CAP) · Drug: Encorafenib first formulation · Drug: Encorafenib second formulation · Drug: Rabeprazole tablet

  • Experimental
    Four Period Treatment Sequence: PPI Effect Second Formulation

    Participants will receive a single encorafenib dose of the second formulation, a single encorafenib dose of the second formulation, a single encorafenib dose of the formulated capsule (CAP), and a single encorafenib dose of the second formulation after administration of 20 mg rabeprazole every evening for 5 days.

    Drug: Encorafenib capsule formulation (CAP) · Drug: Encorafenib first formulation · Drug: Encorafenib second formulation · Drug: Rabeprazole tablet

Interventions

  • DrugEncorafenib capsule formulation (CAP)

    A single encorafenib dose of the CAP formulation

  • DrugEncorafenib first formulation

    first formulation

  • DrugEncorafenib second formulation

    second formulation

  • Proton-pump inhibitor

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time (AUCinf) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

    AUCinf for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated by AUClast + (Clast/kel), where AUClast was the area under the plasma concentration-time profile from time zero to last quantifiable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was first-order elimination rate constant.

    Time frame: Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose

  2. Maximum Observed Plasma Concentration (Cmax) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

    Cmax for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were observed directly from data.

    Time frame: Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose

  3. Area Under the Plasma Concentration-Time Profile From Time Zero to Last Quantifiable Concentration (AUClast) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

    AUClast for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated using Linear/Log trapezoidal method.

    Time frame: Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose

Secondary outcomes

  1. Time for Cmax (Tmax) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

    Tmax for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were observed directly from data as time of first occurrence.

    Time frame: Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose

  2. Terminal Half-Life (t½) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

    t½ for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated by Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.

    Time frame: Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose

  3. Apparent Clearance (CL/F) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

    CL/F for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated by Dose/AUCinf after oral dose.

    Time frame: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose

  4. Apparent Volume of Distribution (Vz/F) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

    Vz/F for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated by Dose/(AUCinf \* kel) after oral dose.

    Time frame: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. Any AEs occurring following start of treatment were considered as treatment emergent adverse event (TEAE). Events that occurred during follow-up within the lag time of up to 28 days after the last encorafenib dose were counted as treatment emergent and attributed to the last treatment taken. Events that occurred during the washout period (up to 28 days from the last treatment) between study periods were counted as treatment emergent and attributed to the previous treatment taken.

    Time frame: Baseline up to Day 28 after the last encorafenib dose (the total duration of the study was approximately 60 days from baseline)

  6. Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality

    Haematological, clinical chemistry (serum) and urinalysis safety tests were assessed against the criteria specified in the sponsor reporting standards. The assessment did not take into account whether each participants's baseline test result was within or outside the laboratory reference range for the particular laboratory parameter. The baseline measurement for safety laboratory tests for all periods was the predose measurement on Day -1 of Period 1. Only those categories in which at least 1 participant had data were reported.

    Time frame: Baseline, and at early discontinuation or at the discretion of the investigator (the total duration of the study was approximately 60 days from baseline)

  7. Number of Participants Meeting Vital Signs Categorical Criteria

    Supine blood pressure (BP) and pulse rate (PR) were measured at times specified. For Periods 1 to 3, the baseline measurement was the predose measurement on Day -1 of each period. For Period 4, the baseline measurement was the predose measurement on Day -1 of Period 3. The reported categories included: systolic blood pressure (SBP)\>=90mmHg; change from baseline (CFB) in SBP\>=30mmHg; diastolic blood pressure (DBP)\<50mmHg; CFB in DBP\>=20mmHg; PR\<40 beats per minute (bpm) or PR\>120bpm. Only those categories in which at least 1 participant had data were provided.

    Time frame: Baseline, 0 and 2 hours postdose in each period, and at early discontinuation (the total duration of the study was approximately 60 days from baseline)

  8. Number of Participnts With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Absolute values and changes from baseline in PR, QT, QRS, heart rate and QTcF were summarized by protocol pre-defined categorization criterion. QTcF were derived using Fridericia's heart rate correction formula. For each period, triplicate ECGs were conducted predose on Day 1; all other ECG measurements were single ECGs. The baseline ECG value was the average of the triplicate ECG measurements collected before dose administration on Day 1. Changes from baseline were defined as the change between the postdose ECG measurement and the derived baseline ECG.

    Time frame: Baseline, 0 and 2 hours postdose in each period, and at early discontinuation (the total duration of the study was approximately 60 days from baseline)

07

Results

Posted Feb 23, 2024

Participant flow

Period 1
Participant flow — Period 1
MilestoneEncorafenib 75 mg eMCC=>75 mg eMCCL=>75 mg CAP=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg eMCC=>75 mg CAP=>75 mg eMCCL=>75 mg eMCCL+20 mg RabeprazoleEncorafenib 75 mg eMCCL=>75 mg CAP=>75 mg eMCC=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg eMCCL=>75 m eMCC=>75 mg CAP=>75 mg eMCCL+20 mg RabeprazoleEncorafenib 75 mg CAP=>75 mg eMCC=>75 mg eMCCL=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg CAP=>75 mg eMCCL=>75 mg eMCC=>75 mg eMCCL+20 mg Rabeprazole
Started333333
Completed333333
Not completed000000
Period 2
Participant flow — Period 2
MilestoneEncorafenib 75 mg eMCC=>75 mg eMCCL=>75 mg CAP=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg eMCC=>75 mg CAP=>75 mg eMCCL=>75 mg eMCCL+20 mg RabeprazoleEncorafenib 75 mg eMCCL=>75 mg CAP=>75 mg eMCC=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg eMCCL=>75 m eMCC=>75 mg CAP=>75 mg eMCCL+20 mg RabeprazoleEncorafenib 75 mg CAP=>75 mg eMCC=>75 mg eMCCL=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg CAP=>75 mg eMCCL=>75 mg eMCC=>75 mg eMCCL+20 mg Rabeprazole
Started333333
Completed233333
Not completed100000
Withdrew: Adverse event100000
Period 3
Participant flow — Period 3
MilestoneEncorafenib 75 mg eMCC=>75 mg eMCCL=>75 mg CAP=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg eMCC=>75 mg CAP=>75 mg eMCCL=>75 mg eMCCL+20 mg RabeprazoleEncorafenib 75 mg eMCCL=>75 mg CAP=>75 mg eMCC=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg eMCCL=>75 m eMCC=>75 mg CAP=>75 mg eMCCL+20 mg RabeprazoleEncorafenib 75 mg CAP=>75 mg eMCC=>75 mg eMCCL=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg CAP=>75 mg eMCCL=>75 mg eMCC=>75 mg eMCCL+20 mg Rabeprazole
Started233333
Completed233333
Not completed000000
Period 4
Participant flow — Period 4
MilestoneEncorafenib 75 mg eMCC=>75 mg eMCCL=>75 mg CAP=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg eMCC=>75 mg CAP=>75 mg eMCCL=>75 mg eMCCL+20 mg RabeprazoleEncorafenib 75 mg eMCCL=>75 mg CAP=>75 mg eMCC=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg eMCCL=>75 m eMCC=>75 mg CAP=>75 mg eMCCL+20 mg RabeprazoleEncorafenib 75 mg CAP=>75 mg eMCC=>75 mg eMCCL=>75 mg eMCC+20 mg RabeprazoleEncorafenib 75 mg CAP=>75 mg eMCCL=>75 mg eMCC=>75 mg eMCCL+20 mg Rabeprazole
Started233333
Completed233333
Not completed000000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time (AUCinf) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

AUCinf for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated by AUClast + (Clast/kel), where AUClast was the area under the plasma concentration-time profile from time zero to last quantifiable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was first-order elimination rate constant.

Time frame:
Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time (AUCinf) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole
ng*hr/mL75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time (AUCinf) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole2895 ± 442909 ± 492957 ± 412825 ± 352556 ± 63
Statistical analysis
  • 75 mg Encorafenib eMCC, Fasted vs 75mg Encorafenib CAP, Fasted · Reference/test ratio: 95.25 · 90% CI 90.82 to 99.90
  • 75mg Encorafenib eMCCL, Fasted vs 75mg Encorafenib CAP, Fasted · Reference/test ratio: 96.30 · 90% CI 91.71 to 101.12
  • 75 mg Encorafenib eMCC, Fasted vs 75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted · Reference/test ratio: 96.57 · 90% CI 82.91 to 112.47
  • 75mg Encorafenib eMCCL, Fasted vs 75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted · Reference/test ratio: 88.56 · 90% CI 82.59 to 94.95
PrimaryMaximum Observed Plasma Concentration (Cmax) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

Cmax for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were observed directly from data.

Time frame:
Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole
ng/mL75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Maximum Observed Plasma Concentration (Cmax) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole898.4 ± 46778.2 ± 45845.8 ± 36686.0 ± 43631.7 ± 70
Statistical analysis
  • 75 mg Encorafenib eMCC, Fasted vs 75mg Encorafenib CAP, Fasted · Reference/test ratio: 104.31 · 90% CI 91.40 to 119.04
  • 75mg Encorafenib eMCCL, Fasted vs 75mg Encorafenib CAP, Fasted · Reference/test ratio: 90.35 · 90% CI 79.17 to 103.12
  • 75 mg Encorafenib eMCC, Fasted vs 75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted · Reference/test ratio: 79.66 · 90% CI 58.70 to 108.08
  • 75mg Encorafenib eMCCL, Fasted vs 75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted · Reference/test ratio: 80.78 · 90% CI 64.82 to 100.68
PrimaryArea Under the Plasma Concentration-Time Profile From Time Zero to Last Quantifiable Concentration (AUClast) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

AUClast for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated using Linear/Log trapezoidal method.

Time frame:
Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero to Last Quantifiable Concentration (AUClast) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole
ng*hr/mL75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Area Under the Plasma Concentration-Time Profile From Time Zero to Last Quantifiable Concentration (AUClast) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole2879 ± 442858 ± 482934 ± 412635 ± 372529 ± 65
Statistical analysis
  • 75 mg Encorafenib eMCC, Fasted vs 75mg Encorafenib CAP, Fasted · Reference/test ratio: 95.34 · 90% CI 90.37 to 100.59
  • 75mg Encorafenib eMCCL, Fasted vs 75mg Encorafenib CAP, Fasted · Reference/test ratio: 94.67 · 90% CI 89.73 to 99.88
  • 75 mg Encorafenib eMCC, Fasted vs 75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted · Reference/test ratio: 95.76 · 90% CI 84.10 to 109.04
  • 75mg Encorafenib eMCCL, Fasted vs 75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted · Reference/test ratio: 88.31 · 90% CI 82.36 to 94.70
SecondaryTime for Cmax (Tmax) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

Tmax for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were observed directly from data as time of first occurrence.

Time frame:
Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose
Reported as:
Median · hr
Time for Cmax (Tmax) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole
hr75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Time for Cmax (Tmax) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole1.00 (0.500 to 3.00)1.00 (1.00 to 1.50)1.5 (1.00 to 3.00)1.25 (1.00 to 2.52)1.00 (0.500 to 3.00)
SecondaryTerminal Half-Life (t½) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

t½ for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated by Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.

Time frame:
Day 1 predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose
Reported as:
Mean · hour
Terminal Half-Life (t½) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole
hour75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Terminal Half-Life (t½) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole4.691 ± 1.56804.850 ± 2.05884.730 ± 1.74164.710 ± 2.37145.350 ± 2.0893
SecondaryApparent Clearance (CL/F) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

CL/F for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated by Dose/AUCinf after oral dose.

Time frame:
0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose
Reported as:
Geometric mean · L/hr
Apparent Clearance (CL/F) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole
L/hr75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Apparent Clearance (CL/F) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole25.91 ± 4425.81 ± 4925.38 ± 4126.53 ± 3429.34 ± 64
SecondaryApparent Volume of Distribution (Vz/F) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole

Vz/F for encorafenib eMCC, eMCCL and CAP formulations (75 mg, single dose administration), and for encorafenib eMCC and eMCCL formulations (75 mg, single dose administration) following 5 days of rabeprazole 20 mg daily were calculated by Dose/(AUCinf \* kel) after oral dose.

Time frame:
0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 hours postdose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole
Liters75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Apparent Volume of Distribution (Vz/F) Following Single Oral Doses of Encorafenib 75 mg Alone and With Rabeprazole166.1 ± 46165.1 ± 49161.7 ± 46159.3 ± 29209 ± 56
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. Any AEs occurring following start of treatment were considered as treatment emergent adverse event (TEAE). Events that occurred during follow-up within the lag time of up to 28 days after the last encorafenib dose were counted as treatment emergent and attributed to the last treatment taken. Events that occurred during the washout period (up to 28 days from the last treatment) between study periods were counted as treatment emergent and attributed to the previous treatment taken.

Time frame:
Baseline up to Day 28 after the last encorafenib dose (the total duration of the study was approximately 60 days from baseline)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Participants75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Participants with AEs (All Causalities)1111815
Participants with AEs (Treatment related)119815
Participants with SAEs (All Causalities)00000
Participants with severe (including fatal) adverse events (All Causalities)00000
SecondaryNumber of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality

Haematological, clinical chemistry (serum) and urinalysis safety tests were assessed against the criteria specified in the sponsor reporting standards. The assessment did not take into account whether each participants's baseline test result was within or outside the laboratory reference range for the particular laboratory parameter. The baseline measurement for safety laboratory tests for all periods was the predose measurement on Day -1 of Period 1. Only those categories in which at least 1 participant had data were reported.

Time frame:
Baseline, and at early discontinuation or at the discretion of the investigator (the total duration of the study was approximately 60 days from baseline)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality
Participants75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
HEMATOLOGY - Monocytes/Leukocytes (%) > 1.2 x Upper Limit of Normal (ULN)00030
CLINICAL CHEMISTRY - Urate (mg/dL) > 1.2x ULN00010
URINALYSIS - Urobilinogen (EU) >= 100001
SecondaryNumber of Participants Meeting Vital Signs Categorical Criteria

Supine blood pressure (BP) and pulse rate (PR) were measured at times specified. For Periods 1 to 3, the baseline measurement was the predose measurement on Day -1 of each period. For Period 4, the baseline measurement was the predose measurement on Day -1 of Period 3. The reported categories included: systolic blood pressure (SBP)\>=90mmHg; change from baseline (CFB) in SBP\>=30mmHg; diastolic blood pressure (DBP)\<50mmHg; CFB in DBP\>=20mmHg; PR\<40 beats per minute (bpm) or PR\>120bpm. Only those categories in which at least 1 participant had data were provided.

Time frame:
Baseline, 0 and 2 hours postdose in each period, and at early discontinuation (the total duration of the study was approximately 60 days from baseline)
Reported as:
Count of participants · Participants
Number of Participants Meeting Vital Signs Categorical Criteria
Participants75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
Number of Participants Meeting Vital Signs Categorical Criteria10000
SecondaryNumber of Participnts With Clinically Significant Electrocardiogram (ECG) Abnormalities

Absolute values and changes from baseline in PR, QT, QRS, heart rate and QTcF were summarized by protocol pre-defined categorization criterion. QTcF were derived using Fridericia's heart rate correction formula. For each period, triplicate ECGs were conducted predose on Day 1; all other ECG measurements were single ECGs. The baseline ECG value was the average of the triplicate ECG measurements collected before dose administration on Day 1. Changes from baseline were defined as the change between the postdose ECG measurement and the derived baseline ECG.

Time frame:
Baseline, 0 and 2 hours postdose in each period, and at early discontinuation (the total duration of the study was approximately 60 days from baseline)
Reported as:
Count of participants · Participants
Number of Participnts With Clinically Significant Electrocardiogram (ECG) Abnormalities
Participants75 mg Encorafenib eMCC, Fasted75mg Encorafenib eMCCL, Fasted75mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
PR INTERVAL (MSEC) value >= 300 msec or %Chg>=25/50%00000
QRS COMPLEX (MSEC) Value >=140 msec or %Chg>=50%00000
QT INTERVAL (MSEC) Value >=500 msec00000
QTCF (MSEC) 450 msec <= Value < 480 msec or 480 msec <= Value < 500 msec or Value > 500 msec00000
QTCF (MSEC) 30 msec <= Chg < 60 msec or Chg > 60 msec00000

Adverse events

Collected over Baseline up to Day 28 after the last encorafenib dose. The total duration of the study was approximately 60 days from baseline.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
75 mg Encorafenib eMCC, Fasted0/18 (0%)0/18 (0%)11/18 (61.1%)
75 mg Encorafenib eMCCL, Fasted0/18 (0%)0/18 (0%)11/18 (61.1%)
75 mg Encorafenib CAP, Fasted0/17 (0%)0/17 (0%)8/17 (47.1%)
75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted0/8 (0%)0/8 (0%)1/8 (12.5%)
75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted0/9 (0%)0/9 (0%)5/9 (55.6%)
Most frequent other events
Showing 10 of 30
Most frequent other events
Event75 mg Encorafenib eMCC, Fasted75 mg Encorafenib eMCCL, Fasted75 mg Encorafenib CAP, Fasted75mg Encorafenib eMCC + 20 mg Rabeprazole, Fasted75mg Encorafenib eMCCL + 20 mg Rabeprazole, Fasted
HeadacheNervous system disorders4/182/185/171/82/9
Feeling hotGeneral disorders4/184/181/170/80/9
DyspepsiaGastrointestinal disorders0/180/180/171/80/9
Hot flushVascular disorders0/181/182/170/80/9
Paraesthesia oralGastrointestinal disorders1/181/180/170/81/9
ChillsGeneral disorders1/180/180/170/81/9
Facial painGeneral disorders0/180/180/170/81/9
FatigueGeneral disorders0/182/180/170/80/9
Decreased appetiteMetabolism and nutrition disorders0/180/180/170/81/9
DizzinessNervous system disorders1/180/180/170/81/9

Baseline characteristics

Baseline analysis population included all enrolled participants.

Age, Continuous
Age, Continuous(Years)All Participants
Mean (SD)46.5 ± 15.93
Age, Customized
Age, Customized(Participants)All Participants
18-44 Years9
45-64 Years7
>=65 Years2
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female5
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
White7
Black or African American8
Asian1
American Indian or Alaska Native1
Black or African American, White1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Hispanic or Latino5
Not Hispanic or Latino13
08

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Sep 2022, 2 months.

Results were first posted in Feb 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Jul 6, 2022
StartActual
Jul 1, 2022
Primary completionActual
Sep 30, 2022
CompletionActual
Sep 30, 2022
Results first posted
Feb 23, 2024
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05446142
Lead sponsor
Pfizer
Collaborators
Ono Pharmaceutical Co. Ltd, Pierre Fabre Laboratories
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Jul 1, 2022
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Results posted
Feb 23, 2024
Last update
Feb 23, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion